Pharminent · Daily Brief
October 28, 2026
Regulatory & Approvals
AbbVie files for FDA approval of etentamig in multiple myeloma
AbbVie has filed for FDA approval of etentamig, a BCMAxCD3 bispecific antibody, in multiple myeloma.
Pharmaphorum →$ABBV
FDA details quicker approval pathway for personalized gene therapies
The FDA issued new details on a faster approval pathway for personalized gene therapies, using an “individualized feature space” approach. Rare disease advocates welcomed the move.
STAT →
Arrowhead wins UK marketing authorization for Redemplo in FCS
Arrowhead Pharmaceuticals received marketing authorization from the UK MHRA for Redemplo as an adjunct to diet to reduce triglyceride levels in adults with familial chylomicronemia syndrome.
Pharmaceutical Technology →
FDA grants orphan drug status to Octant’s OCT-980 for retinitis pigmentosa
The FDA granted orphan drug designation to Octant’s OCT-980, an investigational oral small molecule, for the treatment of retinitis pigmentosa.
Pharmaceutical Technology →
Clinical Data
Lilly says retatrutide beat Novo’s Ozempic in diabetes study
Lilly reported that its “triple-G” drug retatrutide outperformed Novo’s Ozempic in a diabetes study.
STAT →$NVO$LLY
Deals & Partnerships
Ferring to acquire fertility startup Gameto for up to $1.38B
Switzerland’s Ferring Pharmaceuticals agreed to acquire US fertility startup Gameto for up to $1.38 billion, gaining rights to a technology intended to simplify the in vitro fertilization process.
BioPharma Dive →
Teva acquires BXCL501 for $57.5M upfront from BioXcel
Teva acquired BXCL501 from BioXcel for $57.5 million upfront, and Rumi Therapeutics entered an option agreement with Enthorin for a PDE2 inhibitor for Fragile X.
PharmExec →
Business & Finance
Artiva to end autoimmune cell therapy work and cut staff
Artiva Biotherapeutics said it will discontinue its autoimmune cell therapy work and cut staff after patient deaths and a data shortfall, attributing one fatality to a drug used to prepare patients for cell therapy rather than to the cell therapy itself.
BioPharma Dive →
Forwarded this? Get your copy free
Sign up free →
Pharminent — Competitive Intelligence Suite · Tickers link to Yahoo Finance for reference only. Editorial framings are analysis, not investment advice. © 2026.